$-0.42 EPS Expected for T2 Biosystems, Inc. (TTOO); 1 Analysts Covering Aircastle Limited (AYR)

February 9, 2018 - By Migdalia James

Analysts expect T2 Biosystems, Inc. (NASDAQ:TTOO) to report $-0.42 EPS on February, 15.They anticipate $0.05 EPS change or 10.64% from last quarter’s $-0.47 EPS. After having $-0.45 EPS previously, T2 Biosystems, Inc.’s analysts see -6.67% EPS growth. The stock decreased 3.20% or $0.15 during the last trading session, reaching $4.54. About 150,815 shares traded. T2 Biosystems, Inc. (NASDAQ:TTOO) has declined 60.66% since February 9, 2017 and is downtrending. It has underperformed by 77.36% the S&P500.

Among 14 analysts covering Aircastle (NYSE:AYR), 1 have Buy rating, 1 Sell and 12 Hold. Therefore 7% are positive. Aircastle had 39 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Thursday, September 21. The firm has “Hold” rating given on Monday, September 11 by Cowen & Co. Wells Fargo downgraded the shares of AYR in report on Thursday, April 14 to “Market Perform” rating. DA Davidson upgraded Aircastle Limited (NYSE:AYR) on Friday, February 12 to “Buy” rating. The firm earned “Neutral” rating on Friday, November 3 by Credit Suisse. Citigroup maintained Aircastle Limited (NYSE:AYR) rating on Tuesday, March 15. Citigroup has “Buy” rating and $26 target. Barclays Capital downgraded Aircastle Limited (NYSE:AYR) on Friday, April 15 to “Underweight” rating. The firm has “Buy” rating by Deutsche Bank given on Friday, February 12. The company was downgraded on Thursday, May 5 by Deutsche Bank. The firm has “Neutral” rating given on Tuesday, February 28 by Bank of America. See Aircastle Limited (NYSE:AYR) latest ratings:

08/12/2017 Broker: Citigroup Rating: Hold New Target: $25.0 Initiate
03/11/2017 Broker: Credit Suisse Rating: Neutral Old Target: $25 New Target: $26 Maintain
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $25.0 Maintain
16/10/2017 Broker: Cowen & Co Rating: Hold New Target: $26.0 Maintain
21/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $25.0 Maintain
11/09/2017 Broker: Cowen & Co Rating: Hold New Target: $26.0 Maintain

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The company has market cap of $162.65 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. It currently has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

Among 9 analysts covering T2 Biosystems Inc (NASDAQ:TTOO), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. T2 Biosystems Inc had 19 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) has “Underweight” rating given on Wednesday, March 15 by Morgan Stanley. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 2. H.C. Wainwright maintained the stock with “Buy” rating in Friday, November 3 report. Canaccord Genuity maintained it with “Buy” rating and $9 target in Tuesday, August 2 report. The firm earned “Buy” rating on Monday, October 30 by Canaccord Genuity. The firm earned “Neutral” rating on Tuesday, July 21 by BTIG Research. Janney Capital downgraded the stock to “Neutral” rating in Tuesday, April 12 report. The firm earned “Buy” rating on Thursday, September 3 by BTIG Research. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) has “Strong Buy” rating given on Wednesday, July 20 by WBB Securities. H.C. Wainwright maintained it with “Buy” rating and $8.0 target in Thursday, January 25 report.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.01, from 1.08 in 2017Q2. It is positive, as 14 investors sold Aircastle Limited shares while 41 reduced holdings. 22 funds opened positions while 38 raised stakes. 47.77 million shares or 0.31% less from 47.91 million shares in 2017Q2 were reported. Moreover, Morgan Stanley has 0% invested in Aircastle Limited (NYSE:AYR). Affinity Invest Advsr Llc holds 0.03% or 12,160 shares in its portfolio. Denali Advsr Limited owns 173 shares or 0% of their US portfolio. Fifth Third Bancshares holds 0% or 16,010 shares in its portfolio. Alliancebernstein L P reported 0% of its portfolio in Aircastle Limited (NYSE:AYR). Lsv Asset Management invested 0.14% in Aircastle Limited (NYSE:AYR). Tradewinds Cap Ltd Liability Corp has invested 0.01% in Aircastle Limited (NYSE:AYR). Invesco has invested 0% in Aircastle Limited (NYSE:AYR). Ontario Teachers Pension Plan Board owns 7.89M shares or 2.33% of their US portfolio. Advisors Cap Management Ltd Limited Liability Company reported 0.68% in Aircastle Limited (NYSE:AYR). Geode Capital Limited owns 440,655 shares. Northern Corp invested in 0.01% or 2.28 million shares. Prudential Fincl has 0.02% invested in Aircastle Limited (NYSE:AYR). California State Teachers Retirement reported 76,175 shares stake. Texas Yale Capital holds 15,575 shares.

The stock decreased 3.28% or $0.73 during the last trading session, reaching $21.54. About 218,002 shares traded. Aircastle Limited (NYSE:AYR) has risen 8.43% since February 9, 2017 and is uptrending. It has underperformed by 8.27% the S&P500.

Aircastle Limited, through its subsidiaries, acquires, leases, and sells commercial jet aircraft to airlines. The company has market cap of $1.70 billion. The firm also invests in other aviation assets. It has a 10.57 P/E ratio. As of December 31, 2016, its aircraft portfolio comprised 206 aircraft leased to 71 lessees located in 36 countries.